Featured Articles
PREFILLED SYRINGES - Making a Prefilled Syringe Smart: Technological Solutions to Advance Patient Care & Clinical Trial Outcomes
Salvatore Forte, MS, believes adherence to the dosing regimen, as well as compliance to the injection protocol, are essential for treatment success in both these use-cases. Hence, the request for a connected, smart PFS is growing just as much to tackle poor medication adherence and compliance issues.
CLINICAL TRIALS - Digital Endpoint Integration in Clinical Trials: Key Considerations & Nuances Per Therapeutic Focus
Tapan Raval and Ganesh Gundi, MD, say enhancing the patient experience and reducing burden is key in today’s drug development landscape, and DHTs can certainly play a positive role in that.
DRUG DISCOVERY - Benefits of Acoustic Liquid Handling in Drug Discovery
John Fuller, PhD, believes automated acoustic liquid dispensing technology is a game changer – whether deployed as a stand-alone instrument, in a scaled-up workstation, or as part of fully integrated systems – when it comes to handling complexity in efficient and cost-effective ways.
DATA-SHARING PLATFORM - How to Overcome the Challenge of Differing Digital Maturity Levels in Biopharmaceutical Supply Chains
David Brick, MS, and Harlan Knapp, MS, review how the efficient and timely delivery of therapeutics with complex manufacturing needs cannot be achieved by simply unifying the entire pharmaceutical landscape within the most advanced digital maturity level. A better approach is to implement a flexible data-sharing platform that can accommodate partners with different data management capabilities.
VACCINE DEVELOPMENT - A Healthier Global Population Through a Universal Influenza & Multi-Virus Vaccine
Jeff Fischer, MBA, says we need to have an eye toward universal influenza or multi-virus vaccines that have the ability to provide broad coverage as viral strains continue to evolve.
THERAPEUTIC FOCUS - TTHX1114: Improving Outcomes for High-Risk Patients After Cataract Surgery
David Eveleth, PhD, says in many cases, high-risk patients have few options for complication-free treatment of cataracts or other degenerative eye disorders. By filling this unmet need, TTHX1114 has the potential to significantly improve vision health, enhance the well-being of high-risk individuals, and alleviate economic burden on healthcare systems and economies.
ENGINEERING BIOLOGY - Scaling Engineering Biology to Accelerate Advances in Healthcare
Raquel Sanches-Kuiper and Matthew Hayes, PhD, say the development of a benchtop synthesis platform has the potential to expedite the discovery and development time for drugs and biotherapeutics, greatly accelerating the rate at which engineering biology can shape the future of healthcare.
Dyadic Advances Collaboration With Israel Institute for Biological Research Targeting Bio-Threats & Emerging Disease Solutions
Dyadic International, Inc. and Israel Institute for Biological Research (IIBR) recently announced it has advanced its collaboration with IIBR and its commercial arm Life Science…
SPECIAL FEATURE - Outsourcing Analytical Testing: AI Could Transform Analytical Labs
Contributor Cindy H. Dubin presents how today’s leading analytical testing service providers are taking advantage of AI and other types of automation and innovative technologies.
EXECUTIVE INTERVIEW - How Resilience Is Bringing Forward Thinking to Disrupt the Biomanufacturing Landscape to Increase Access to Medicines
Syed T. Husain, Chief Commercial Officer of Resilience, discusses how the company became an industry-leading service provider in less than 4 years.
FORMULATION FORUM - Lipid Nanoparticles – Carriers for Nucleic Acids Delivery
Shaukat Ali, PhD, and Jim Huang, PhD, describe the role of individual components in aggregation, packing, stability, efficacy, and potency of nucleic acids, the understanding of which is important to achieve better designed and smarter formulations, and robust scale up and manufacturing of LNPs.
SPECIAL ROUNDTABLE - Leadership Panel: 4 Trends That Will Have the Most Impact on Drug Development in 2024
Contributor Cindy H. Dubin asked some of today’s life science leaders what they expect will have the greatest impact on drug development in 2024 and beyond.
DRUG DISCOVERY - Overcoming Traditional Challenges: Innovative Chemoproteomics Strategies to Revolutionize Drug Discovery
Ping Cao, PhD, and Irene Yuan believe their chemoproteomic platform offers a distinct advantage by enabling the simultaneous exploration of the entire proteome, setting it apart from other drug discovery technologies that typically focus on individual targets.
EXECUTIVE INTERVIEW - Samsung Biologics: Exploring The Evolving Biopharma Landscape
Kevin Sharp, Senior VP & Head of Sales for Samsung Biologics, discusses the evolving biopharma space, exploring current challenges, and the demand for sustainable solutions.
DRUG DEVELOPMENT - Using a Novel Deep Cyclic Inhibition Mechanism to Treat Broad Range of RAS-Mutant Cancers
Ben Zeskind, PhD, addresses the question: rather than targeting individual RAS mutations and treating chronically, is it possible to achieve broad therapeutic activity in a way that focuses on malignant cells while minimizing damage to healthy cells?
CLINICAL TRIALS - The Power of AI in Overcoming Patient Diversity Challenges
Isaac Bentwich, PhD, explores why patient diversity is such a challenge for clinical trials, where that pain is often felt the most, some of the regulatory, technological, and industry changes already underway to solve the clinical trial gap, and where AI changes the future of patient diversity.
SUPPLY CHAIN VISIBILITY - New Tracking Technologies Driving Improvements to Reduce Drug Shortages, Expedite Recalls, Protect & Inform Patients
Tracy Nasarenko says new technologies are being leveraged along with industry standards to enable full visibility across the entire supply chain, tracking products all the way from manufacturer to end user.
PHARMACOVIGILANCE AUTOMATION - Improving CRO Efficiency Through Automation
Emmanuel Belabe says many CROs believe they’ve reached a breaking point as they work to keep up with rising case volumes, data complexities, and changing regulations. To combat these pressures, CROs need access to modern pharmacovigilance (PV) automation that promotes flexibility, scalability, efficiency, and cost-effectiveness.
ARTIFICIAL INTELLIGENCE PLATFORM - Advancing Precision Medicine With bfLEAP™: Next Generation AI for Drug Development
Thomas Hazel, PhD, and JT Koffenberger explore the technical architecture and capabilities of bfLEAP, delving into its ML algorithms, proprietary clustering techniques, and visually understandable outputs, examine some of the potential use cases for the platform in drug development, and discuss future developments.
2024 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
